Profile data is unavailable for this security.
About the company
Shanghai Fosun Pharmaceutical Group Co Ltd is a China-based company mainly engaged in the research and development, manufacturing and sales of pharmaceutical products. The Company operates in five segments. Pharmaceutical segment is mainly engaged in the manufacturing of innovative drugs, mature pharmaceutical products and vaccines. Medical Devices and Medical Diagnostics segment is mainly engaged in the manufacturing and sales of medical cosmetic devices such as molecular diagnosis, immunodiagnosis, and microbial diagnosis. Medical Health Services segment is mainly engaged in the operation of an online and offline integrated medical service platform. Pharmaceutical Distribution and Retail segment is mainly engaged in the wholesale and retail of pharmaceutical products. Others segment is engaged in other pharmaceutical-related businesses. The Company's products are mainly used in the treatment of tumors, immunity, central nervous system and other fields.
- Revenue in HKD (TTM)45.20bn
- Net income in HKD3.67bn
- Incorporated1995
- Employees40.23k
- LocationShanghai Fosun Pharmaceutical Group Co LtdBuilding A, No. 1289 Yishan RoadSHANGHAI 200233ChinaCHN
- Phone+86 2 133987870
- Fax+86 2 133987871
- Websitehttps://www.fosunpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grifols SA | 69.63bn | 3.45bn | 62.94bn | 23.83k | 20.22 | 1.45 | 7.55 | 0.9039 | 0.546 | 0.546 | 11.02 | 7.62 | 0.3746 | 1.35 | 7.15 | 315,451.40 | 2.28 | 1.72 | 2.99 | 2.21 | 39.09 | 38.85 | 6.09 | 5.43 | 0.9283 | 2.52 | 0.5621 | -- | 9.41 | 7.18 | 270.81 | -24.15 | -2.07 | -- |
| Ono Pharmaceutical Co Ltd | 25.93bn | 3.18bn | 64.61bn | 4.29k | 19.17 | 1.42 | 12.77 | 2.49 | 132.76 | 132.76 | 1,084.01 | 1,786.88 | 0.4702 | 2.14 | 3.38 | 118,811,500.00 | 5.77 | 10.78 | 6.61 | 12.37 | 69.79 | 73.23 | 12.27 | 21.23 | 2.56 | 125.26 | 0.1283 | 36.33 | -3.14 | 10.73 | -60.89 | -3.47 | -18.66 | 12.20 |
| Kyowa Kirin Co Ltd | 25.29bn | 3.41bn | 69.36bn | 5.67k | 20.24 | 1.52 | 14.62 | 2.74 | 128.07 | 128.07 | 949.13 | 1,706.50 | 0.4568 | 1.82 | 2.99 | -- | 6.16 | 6.40 | 7.33 | 7.37 | 74.25 | 74.99 | 13.49 | 14.37 | 2.35 | -- | -- | 46.19 | 0.2559 | 9.31 | 11.98 | 7.35 | 19.80 | 7.10 |
| Axsome Therapeutics Inc | 4.39bn | -1.79bn | 71.40bn | 683.00 | -- | 123.65 | -- | 16.28 | -4.67 | -4.67 | 11.40 | 1.47 | 0.9121 | 2.40 | 3.50 | 821,761.40 | -37.30 | -59.62 | -68.09 | -80.32 | 91.86 | -- | -40.89 | -134.06 | 1.50 | -28.27 | 0.7255 | -- | 42.53 | -- | -20.05 | -- | 75.71 | -- |
| Halozyme Therapeutics, Inc. | 9.71bn | 4.65bn | 73.01bn | 350.00 | 16.70 | 18.53 | 13.79 | 7.52 | 4.76 | 4.76 | 9.90 | 4.29 | 0.5728 | 1.21 | 3.93 | 3,551,006.00 | 27.45 | 22.20 | 35.10 | 25.70 | 84.55 | 80.85 | 47.91 | 45.39 | 1.37 | -- | 0.7499 | 0.00 | 22.44 | 38.95 | 57.71 | -- | 21.50 | -- |
| Krka dd Novo Mesto | 18.61bn | 3.69bn | 73.81bn | 13.11k | 18.66 | 3.24 | 16.20 | 3.97 | 13.02 | 13.02 | 65.60 | 75.06 | 0.6947 | 1.31 | 3.44 | 156,823.60 | 13.79 | 12.80 | 16.67 | 15.31 | 57.71 | 57.39 | 19.85 | 19.11 | 2.57 | -- | 0.0082 | 59.40 | 5.71 | 5.04 | 13.71 | 7.77 | 0.8404 | 14.19 |
| Mankind Pharma Ltd | 11.92bn | 1.53bn | 74.04bn | 27.00k | 48.51 | -- | 32.12 | 6.21 | 42.95 | 43.05 | 334.94 | -- | -- | -- | -- | 5,126,748.00 | -- | 14.93 | -- | 19.39 | 71.39 | 67.59 | 13.00 | 17.70 | -- | 3.64 | -- | 0.00 | 18.98 | 15.79 | 3.90 | 14.03 | 18.41 | -- |
| Eisai Co Ltd | 41.15bn | 2.18bn | 74.21bn | 13.51k | 32.95 | 1.58 | 17.41 | 1.80 | 151.67 | 151.67 | 2,866.61 | 3,153.46 | 0.5537 | 0.7996 | 3.33 | 59,839,040.00 | 3.04 | 3.81 | 4.22 | 5.14 | 77.75 | 77.47 | 5.48 | 6.44 | 1.54 | -- | 0.2015 | 98.01 | 6.42 | 2.56 | 9.49 | -17.54 | -14.48 | 0.00 |
| Shanghai Fosun Pharmaceutical (Group) | 45.20bn | 3.67bn | 74.81bn | 40.23k | 14.94 | 1.01 | 8.88 | 1.66 | 1.38 | 1.38 | 16.95 | 20.30 | 0.341 | 2.95 | 4.73 | 1,114,443.00 | 3.47 | 3.90 | 5.97 | 6.50 | 47.37 | 48.67 | 10.17 | 9.89 | 0.7661 | -- | 0.3786 | 30.25 | -0.8209 | 7.58 | 15.53 | -3.57 | 2.17 | -3.06 |
| Zydus Lifesciences Ltd | 22.46bn | 4.25bn | 78.87bn | 27.92k | 18.55 | -- | 15.09 | 3.51 | 49.08 | 49.08 | 259.31 | -- | -- | -- | -- | 9,345,309.00 | -- | 10.92 | -- | 16.35 | 73.12 | 63.12 | 18.91 | 16.73 | -- | -- | -- | 17.81 | 18.90 | 10.27 | 17.96 | 30.92 | 13.63 | 25.74 |
| Jazz Pharmaceuticals PLC | 32.50bn | -2.88bn | 78.98bn | 2.80k | -- | 2.55 | 31.80 | 2.43 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| WuXi XDC Cayman Inc | 5.76bn | 1.50bn | 81.77bn | 2.27k | 56.25 | 9.29 | 49.59 | 14.21 | 1.16 | 1.16 | 4.43 | 7.00 | 0.5687 | 21.58 | 3.31 | 2,820,236.00 | 14.83 | -- | 19.71 | -- | 33.01 | -- | 26.08 | -- | 2.14 | -- | 0.1225 | -- | 90.80 | -- | 277.24 | -- | -- | -- |
Data as of Feb 16 2026. Currency figures normalised to Shanghai Fosun Pharmaceutical Group Co Ltd's reporting currency: Hong Kong Dollar HKD
14.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 18.34m | 3.32% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 12.92m | 2.34% |
| BlackRock Financial Management, Inc.as of 06 Feb 2026 | 9.75m | 1.77% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 9.28m | 1.68% |
| BlackRock Investment Management (UK) Ltd.as of 06 Feb 2026 | 6.72m | 1.22% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 5.90m | 1.07% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 5.67m | 1.03% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2025 | 3.82m | 0.69% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 3.73m | 0.68% |
| BlackRock (Netherlands) BVas of 06 Feb 2026 | 2.30m | 0.42% |
More ▼
Data from 30 Jun 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
